Cannabis Industry Digest For October 23 2026

This week’s cannabis news spans consumer safety, sleep science, and territorial market growth. A Colorado state audit found regulatory gaps that left unsafe marijuana products on dispensary shelves for months or even years. New research published in JAMA Network Open cast doubt on cannabis as a sleep aid.

And in the U.S. Virgin Islands, eleven micro-cultivation applications advanced as St. Croix prepared for its second commercial cultivator.

Colorado Audit Finds Marijuana Regulations Put Consumers at Risk

Consumers in Colorado’s regulated recreational marijuana market are at risk of consuming contaminated products due to deficiencies in state regulations, an audit released Monday found. The state audit into how the Colorado Marijuana Enforcement Division regulates marijuana market safety detailed findings similar to those in a September investigative report by The Denver Gazette and ProPublica on delays pulling a marijuana sleep aid pill with ingredients researchers said can cause liver damage.

The audit found unsafe products remained on the market for as long as three years before the enforcement division issued a public warning. From 2023 through 2025, affected products that were the subject of advisories remained on shelves for more than seven months on average. While 24 of the 42 states with marijuana markets rely on private lab staff or an independent third party to collect samples for testing, Colorado marijuana businesses are free to collect their own samples.

Dominique Mendiola, senior director of the Colorado Marijuana Enforcement Division, told legislators during a legislative committee hearing that her agency embraced the audit’s recommendations.

Cannabis and CBD for Insomnia What the Science Says

According to the CDC, 30.5 percent of American adults reported sleeping fewer than seven hours a night in 2024. In a survey of medical cannabis users in the United States and Canada, 46 percent reported using cannabis to manage sleep problems. Cannabis or CBD is not FDA-approved for chronic insomnia.

Working with Harvard’s Kevin Hill and colleagues, the author examined therapeutic cannabis claims in the American Journal of Psychiatry and JAMA, concluding that cannabinoid medical claims have advanced much faster than scientific evidence or convincing randomized clinical trials.

An October 2026 study in JAMA Network Open examined cannabis exposure and sleep in the long-running CARDIA cohort. Greater cumulative cannabis exposure was associated with poorer sleep efficiency, more fragmented sleep, and more time awake after falling asleep. Recent cannabis users also had poorer objectively measured sleep than never-users, despite tending to sleep longer.

However, participants didn’t report correspondingly worse sleep quality.

Virgin Islands Micro Cultivation Applications Advance

Eleven cannabis micro-cultivation applications have advanced to the compliance phase, while a second commercial cultivator on St. Croix is expected to begin operations by the end of the week, according to Office of Cannabis Regulation Executive Director Joanne Moorehead. The updates came during Thursday’s Cannabis Advisory Board meeting, which proceeded without a quorum.

The eleven applications include three from St. John, four from St. Thomas, three from St.

Related Stories

• Federal Grand Jury Indicts Oregon Cannabis CEO Over $1.5 Million Unpaid Taxes
• Illinois Cannabis Prices Drop As State Tax Revenue Falls Below $2 Billion Mark
• Rhode Island Delays Hemp Regulations Amid Looming Federal THC Ban